S-Nitrosoglutathione

From Wikipedia, the free encyclopedia
  (Redirected from S-nitrosoglutathione)
Jump to: navigation, search
S-Nitrosoglutathione
Stereo, skeletal formula of S-nitrosoglutathione ((2S)-2-Amino, -4-{[(1R)-1-carbamoylethyl]carbamoyl})
Identifiers
CAS number 57564-91-7 (2S)-2-Amino, -4-{[(1R)-1-carbamoylethyl]carbamoyl} YesY
PubChem 3514, 10404739 (2S)-2-Amino, -4-{[(1S)-1-carbamoylethyl]carbamoyl}, 104858 (2S)-2-Amino, -4-{[(1R)-1-carbamoylethyl]carbamoyl}, 6603946 (2R)-2-Amino, -4-{[(1S)-1-carbamoylethyl]carbamoyl}
ChemSpider 3394 YesY, 8580177 (2S)-2-Amino, -4-{[(1S)-1-carbamoylethyl]carbamoyl} YesY, 94647 (2S)-2-Amino, -4-{[(1R)-1-carbamoylethyl]carbamoyl} YesY, 5036252 (2R)-2-Amino, -4-{[(1S)-1-carbamoylethyl]carbamoyl} YesY
MeSH S-Nitrosoglutathione
ChEBI CHEBI:50091 YesY
ChEMBL CHEMBL50091 YesY, CHEMBL156747 YesY
RTECS number MC0558000 (2S)-2-Amino, -4-{[(1R)-1-carbamoylethyl]carbamoyl}
Beilstein Reference 3566211 (2S)-2-Amino, -4-{[(1R)-1-carbamoylethyl]carbamoyl}
Jmol-3D images Image 1
Image 2
Properties
Molecular formula C10H16N4O7S
Molar mass 336.32 g mol−1
log P −2.116 (2SR)-2-Amino, -4-{[(1RS)-1-carbamoylethyl]carbamoyl}
Acidity (pKa) 2.212 (2SR)-2-Amino, -4-{[(1RS)-1-carbamoylethyl]carbamoyl}
Basicity (pKb) 11.785 (2SR)-2-Amino, -4-{[(1RS)-1-carbamoylethyl]carbamoyl}
Related compounds
Related alkanoic acids
Related compounds Ethambutol
Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
Infobox references

S-Nitrosoglutathione (GSNO) is an endogenous S-nitrosothiol (SNO) that plays a critical role in nitric oxide (NO) signaling and is a source of bioavailable NO. NO coexists in cells with SNOs that serve as endogenous NO carriers and donors. SNOs spontaneously release NO at different rates and can be powerful terminators of free radical chain propagation reactions, by reacting directly with ROO• radicals, yielding nitro derivatives as end products.[1] NO is generated intracellularly by the nitric oxide synthase (NOS) family of enzymes: nNOS, eNOS and iNOS while the in vivo source of many of the SNOs is unknown. In oxygenated buffers, however, formation of SNOs is due to oxidation of NO to dinitrogen trioxide (N2O3).[2] Some evidence suggests that both exogenous NO and endogenously derived NO from nitric oxide synthases can react with glutathione to form GSNO.

The enzyme GSNO reductase (GSNOR) reduces S-nitrosoglutathione (GSNO) to an unstable intermediate, S-hydroxylaminoglutathione, which then rearranges to form glutathione sulfonamide, or in the presence of GSH, forms oxidized glutathione (GSSG) and hydroxylamine.[3][4][5] Through this catabolic process, GSNOR regulates the cellular concentrations of GSNO and plays a central role in regulating the levels of endogenous S-nitrosothiols and controlling protein S-nitrosylation-based signaling.

The chemical synthesis of GSNO

The generation of GSNO can serve as a stable and mobile NO pool which can effectively transduce NO signaling.[6][7] Unlike other low molecular weight messengers that bind to and activate target cellular receptors, NO signaling is mediated by a coordinating complex between NO and transition metals or target cellular proteins, often via S-nitrosylation of cysteine residues.[8][9][10] Studies suggest that NO metabolism has a significant role in human cardiovascular and respiratory diseases as well as in immune tolerance during organ transplantation.[11][12][13][14]

GSNO in Health and Disease[edit]

GSNO and NO concentrations regulate respiratory function by modulating airway tone and pro- and anti-inflammatory responses in the respiratory tract.[14][15] Because NO is a labile gas and endogenous levels are difficult to manipulate, it has been proposed that exogenous GSNO could be used to regulate circulating levels of NO and NO-derived species, and GSNO could have value in patients with pulmonary diseases such as cystic fibrosis. Consistent with this therapeutic goal, a recent study showed that acute treatment with aerosolized GSNO was well tolerated by cystic fibrosis patients.[14]

SNOs in the hepatic mitochondria appear to influence proper functioning of the liver. Mitochondrial SNO-proteins inhibit Complex I of the electron transport chain; modulate mitochondrial reactive oxygen species (ROS) production; influence calcium-dependent opening of the mitochondrial permeability transition pore; promote selective importation of mitochondrial proteins; and stimulate mitochondrial fission. Altered redox balance plays a crucial role in the pathogenesis of liver diseases including steatosis, steatohepatitis, and fibrosis. The ease of reversibility and the interplay of S-nitrosating and denitrosating enzymatic reactions support the hypothesis that SNOs regulate the mitochondrion through redox mechanisms.[16]

In a study evaluating the effects on ursodeoxycholic acid (UDCA) on bile flow and cirrhosis, NO was found in bile as SNOs, primarily GSNO. UDCA-stimulated biliary NO secretion was abolished by the inhibition of iNOS with L-NAME in isolated perfused livers and also in rat livers depleted of GSH with buthionine sulfoximine. Moreover, the biliary secretion of NO species was significantly diminished in UDCA-infused transport mutant [ATP–binding cassette C2/multidrug resistance–associated protein 2–deficient] rats, and this finding was consistent with the involvement of the glutathione carrier ABCC2/Mrp2 in the canalicular transport of GSNO. It was particularly noteworthy that in cultured normal rat cholangiocytes, GSNO activated protein kinase B, protected against apoptosis, and enhanced UDCA-induced ATP release to the medium.[17] Finally, they demonstrated that retrograde GSNO infusion into the common bile duct increased bile flow and biliary bicarbonate secretion. The study concluded that UDCA-induced biliary secretion of GSNO contributed to stimulating ductal secretion of bile.

References[edit]

  1. ^ de Oliveira CP, de Lima VM, Simplicio FI, Soriano FG, de Mello ES, de Souza HP, Alves VA, Laurindo FR, Carrilho FJ, de Oliveira MG (April 2008). "Prevention and reversion of nonalcoholic steatohepatitis in OB/OB mice by S-nitroso-N-acetylcysteine treatment". J Am Coll Nutr 27 (2): 299–305. doi:10.1080/07315724.2008.10719703. PMID 18689562. 
  2. ^ Giustarini D, Milzani A, Dalle-Donne I, Rossi R (May 2007). "Detection of S-nitrosothiols in biological fluids: a comparison among the most widely applied methodologies". J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 851 (1-2): 124–39. doi:10.1016/j.jchromb.2006.09.031. PMID 17035104. 
  3. ^ Hedberg JJ, Griffiths WJ, Nilsson SJ, Höög JO (March 2003). "Reduction of S-nitrosoglutathione by human alcohol dehydrogenase 3 is an irreversible reaction as analysed by electrospray mass spectrometry". Eur. J. Biochem. 270 (6): 1249–56. doi:10.1046/j.1432-1033.2003.03486.x. PMID 12631283. 
  4. ^ Jensen DE, Belka GK, Du Bois GC (April 1998). "S-Nitrosoglutathione is a substrate for rat alcohol dehydrogenase class III isoenzyme". Biochem. J. 331 (2): 659–68. PMC 1219401. PMID 9531510. 
  5. ^ Staab CA, Alander J, Morgenstern R, Grafström RC, Höög JO (March 2009). "The Janus face of alcohol dehydrogenase 3". Chem. Biol. Interact. 178 (1-3): 29–35. doi:10.1016/j.cbi.2008.10.050. PMID 19038239. 
  6. ^ Dijkers PF, O'Farrell PH (September 2009). "Dissection of a hypoxia-induced, nitric oxide-mediated signaling cascade". Mol. Biol. Cell 20 (18): 4083–90. doi:10.1091/mbc.E09-05-0362. PMC 2743626. PMID 19625446. 
  7. ^ Lima B, Forrester MT, Hess DT, Stamler JS (March 2010). "S-nitrosylation in cardiovascular signaling". Circ. Res. 106 (4): 633–46. doi:10.1161/CIRCRESAHA.109.207381. PMC 2891248. PMID 20203313. 
  8. ^ Derakhshan B, Hao G, Gross SS (July 2007). "Balancing reactivity against selectivity: the evolution of protein S-nitrosylation as an effector of cell signaling by nitric oxide". Cardiovasc. Res. 75 (2): 210–9. doi:10.1016/j.cardiores.2007.04.023. PMC 1994943. PMID 17524376. 
  9. ^ Hess DT, Matsumoto A, Kim SO, Marshall HE, Stamler JS (February 2005). "Protein S-nitrosylation: purview and parameters". Nat. Rev. Mol. Cell Biol. 6 (2): 150–66. doi:10.1038/nrm1569. PMID 15688001. 
  10. ^ Kone BC (August 2006). "S-Nitrosylation: Targets, Controls and Outcomes". Current Genomics 7 (5): 301–10. doi:10.2174/138920206778604340. 
  11. ^ Casey DP, Beck DT, Braith RW (December 2007). "Systemic plasma levels of nitrite/nitrate (NOx) reflect brachial flow-mediated dilation responses in young men and women". Clin. Exp. Pharmacol. Physiol. 34 (12): 1291–3. doi:10.1111/j.1440-1681.2007.04715.x. PMID 17973870. 
  12. ^ Ganz P, Vita JA (October 2003). "Testing endothelial vasomotor function: nitric oxide, a multipotent molecule". Circulation 108 (17): 2049–53. doi:10.1161/01.CIR.0000089507.19675.F9. PMID 14581383. 
  13. ^ Que LG, Liu L, Yan Y, Whitehead GS, Gavett SH, Schwartz DA, Stamler JS (June 2005). "Protection from experimental asthma by an endogenous bronchodilator". Science 308 (5728): 1618–21. doi:10.1126/science.1108228. PMC 2128762. PMID 15919956. .
  14. ^ a b c Snyder AH, McPherson ME, Hunt JF, Johnson M, Stamler JS, Gaston B (April 2002). "Acute effects of aerosolized S-nitrosoglutathione in cystic fibrosis". Am. J. Respir. Crit. Care Med. 165 (7): 922–6. doi:10.1164/ajrccm.165.7.2105032. PMID 11934715. 
  15. ^ Gaston B, Reilly J, Drazen JM, Fackler J, Ramdev P, Arnelle D, Mullins ME, Sugarbaker DJ, Chee C, Singel DJ (December 1993). "Endogenous nitrogen oxides and bronchodilator S-nitrosothiols in human airways". Proc. Natl. Acad. Sci. U.S.A. 90 (23): 10957–61. doi:10.1073/pnas.90.23.10957. PMC 47900. PMID 8248198. 
  16. ^ Piantadosi CA (March 2011). "Regulation of mitochondrial processes by protein S-nitrosylation". Biochim Biophys Acta 1820 (6): 712–21. doi:10.1016/j.bbagen.2011.03.008. PMID 21397666. 
  17. ^ Rodríguez-Ortigosa CM, Banales JM, Olivas I, Uriarte I, Marín JJ, Corrales FJ, Medina JF, Prieto J (August 2010). "Biliary secretion of S-nitrosoglutathione is involved in the hypercholeresis induced by ursodeoxycholic acid in the normal rat". Hepatology 52 (2): 667–77. doi:10.1002/hep.23709. PMID 20683964. 

External links[edit]